Role of Interleukin-6 and Procalcitonin in Evaluating COVID 19 Disease Severity - an Experience at CMH Quetta
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Covid19 Positive Patients
- Sponsor
- FARAH AFZAL
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- Levels of inflammatory biomarkers is raised in accordance with severity of COVID 19
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
Serum Interleukin-6 and Procalcitonin of 100 consenting COVID 19 positive patients from April 2020 - May 2021 were assessed at Pathology department CMH Quetta and the results were correlated with severity of lung involvement on HRCT Chest
Detailed Description
Objective: To explore the relation between Interleukin-6 and Procalcitonin with COVID severity on HRCT Chest Study Design: Randomized Control Trial (Clinical Trials. gov Identifier: NCT04798391) Place and duration of study: Pathology, Radiology \& ENT Department CMH Quetta from April 2020 - May 2021 Methodology: Serum Interleukin-6 and Procalcitonin of 100 consenting COVID 19 positive patients from April 2020 - May 2021 were assessed at Pathology department CMH Quetta and the results were correlated with severity of lung involvement on HRCT Chest Results: Serum Interlukin-6 levels were raised in 97 (97%) patients with mean levels of 20.43 + 19.66 (pg/ml). Serum procalcitonin levels were raised in 95 (95%) patients with mean levels of 0.4331 + 0.24 (ng/ml). A P value of \<0.001 was calculated on Independent Sample T-test for both serum interlukin-6 and serum procalcitonin as correlated with severity of lung involvement on HRCT Chest. Conclusion: Interlukin-6 and procalcitonin are excellent biomarkers for diagnosis and predicting severity of COVID19 pneumonia. Keywords: Covid19 pneumonia, Interlukin-6, procalcitonin.
Investigators
FARAH AFZAL
CLASSIFIED SPECIALIST
Combined Military Hospital, Pakistan
Eligibility Criteria
Inclusion Criteria
- •positive PCR of COVID 19
Exclusion Criteria
- •NEGATIVE PCR of COVID 19
Outcomes
Primary Outcomes
Levels of inflammatory biomarkers is raised in accordance with severity of COVID 19
Time Frame: 2 days
serum Interlukin-6 levels was measured on COBAS-e 411 Immunoassay analyzer using electro chemiluminescence methodology using Roche Interlukin-6 kit with raised levels taken as \> 7 pico gram / milliliter (pg/ml). Serum procalcitonin were also measured by similar methodology using Roche procalcitonin kit with raised levels taken as \> 0.15 nano gram / milliliter (ng/ml). COVID 19 pneumonia was categorized on HRCT chest as Mild with total score 7 or less, moderate with score from 8 - 17, and severe with score more than 18.